Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5071723 | 0.91 | ACHE (0.52) | SIGMAR1ACHEBCHEBACE1CYP1A2 | |
| SCHEMBL11413096 | 0.85 | FUCA1 (0.60) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL16837173 | 0.83 | FUCA1 (0.58) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL4198217 | 0.83 | FUCA1 (0.54) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL21773216 | 0.82 | FUCA1 (0.53) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL21777260 | 0.82 | FUCA1 (0.53) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL21773211 | 0.82 | FUCA1 (0.53) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL21777835 | 0.82 | FUCA1 (0.53) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL21777836 | 0.82 | FUCA1 (0.53) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL21777837 | 0.82 | FUCA1 (0.53) | FUCA1SIGMAR1DRD2DRD3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | disclosed |
| EP-1904495-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007281-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | FUCA1 1256/4885SIGMAR1 317/4885DRD2 563/4885 |
| US-20080255188-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | FUCA1 1402/4885SIGMAR1 366/4885DRD2 467/4885 |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | FUCA1 1335/4885SIGMAR1 291/4885DRD2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.